Bone Biologics (BBLGW) Research & Development (2014 - 2026)

Bone Biologics (BBLGW) has reported Research & Development for 13 consecutive years, with $308747.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 61.13% year-over-year to $308747.0 in Q2 2026; TTM through Jun 2026 was $945360.0, a 56.02% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 50.23% from the prior year.
• Research & Development was $308747.0 for Q2 2026 at Bone Biologics, up from $257197.0 in the prior quarter.
• Over five years, Research & Development peaked at $2.6 million in Q1 2023 and troughed at $17600.0 in Q2 2022.
• A 5-year average of $705084.8 and a median of $423576.0 in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 12941.2% in 2023 and tumbled 90.52% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $755888.0 in 2022, then plunged by 40.85% to $447077.0 in 2023, then soared by 147.07% to $1.1 million in 2024, then slumped by 76.72% to $257197.0 in 2025, then climbed by 20.04% to $308747.0 in 2026.
• The last three Research & Development figures came in at $308747.0 (Q2 2026), $257197.0 (Q4 2025), and $187808.0 (Q3 2025), per Business Quant data.